Exacerbaciones de la EPOC

Se analizan las opciones terapéuticas en base a la mejor evidencia científica disponible.

Autor/a: Shaw D. Aaron. Management and prevention of exacerbations of COPD

INDICE: 1. Desarrollo | 2. Desarrollo

Desarrollo

↵Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med1987;106:196-204.CrossRefMedlineWeb of Science
↵Aaron SD, Vandemheen K, Clinch J, Ahuja J, Brison R, Dickinson G, et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest2002;121:688-96.CrossRefMedlineWeb of Science
↵Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med1998;157:1418-22.CrossRefMedlineWeb of Science
↵Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2014. www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.
↵Rodriguez-Roisin R. Toward a consensus definition of COPD exacerbations. Chest2000;117:398S-401S.CrossRefMedlineWeb of Science
↵Mackay AJ, Donaldson GC, Patel ARC, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med2012;185:1218-24.CrossRefMedlineWeb of Science
↵Leidy N, Murray L. Patient-reported outcome (PRO) measures for clinical trials of COPD: the EXACT and E-RS. COPD2013;10:393-8.CrossRefWeb of Science
↵Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med2008;177:396-401.CrossRefMedlineWeb of Science
↵Xu W, Collet JP, Shapiro S, Lin Y, Yang T, Wang C, et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at one year. Eur Respir J2010;35:1022-30.Abstract/FREE Full Text
↵Aaron SD, Vandemheen K, Fergusson D, Maltais F, Bourbeau J, Balter M, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone/salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med2007;146:545-55.CrossRefMedlineWeb of Science
↵Aaron SD, Fergusson D, Marks GB, Suissa S, Vandemheen KL, Doucette S, et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax2008;63:122-8.Abstract/FREE Full Text
↵Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstuctive pulmonary disease. N Engl J Med2007;356:775-89.CrossRefMedlineWeb of Science
↵Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med2013;369:1491-501.CrossRefMedlineWeb of Science
↵Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge SS, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med2008;359:1543-54.CrossRefMedlineWeb of Science
↵Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MPMH, Beeh KM, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med2011;364:1093-103.CrossRefMedlineWeb of Science
↵Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med2008;177:19-26.CrossRefMedlineWeb of Science
↵Donaldson GC, Seemungal TAR, Patel IS, Bhowmik A, Wilkinson TMA, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest2005;128:1995-2004.CrossRefMedlineWeb of Science
↵Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med2001;163:349-355.CrossRefMedlineWeb of Science
↵Bafadhel M, McKenna S, Terry P, Mistry V, Reid C, Haldar P. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med2012;184:662-71.Web of Science
↵Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med2012;186:716-23.CrossRefMedlineWeb of Science
↵O’Donnell DE, Parker CM. COPD exacerbations. 3: Pathophysiology. Thorax2006;61:354-61.Abstract/FREE Full Text
↵Parker C, Voduc N, Aaron SD, Webb KA, O’Donnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J2005;26:420-8.Abstract/FREE Full Text
↵Sethi S, Evans N, Brydon JB, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med2002;347:465-71.CrossRefMedlineWeb of Science
↵Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med2008;359:2355-65.CrossRefMedlineWeb of Science
↵Seemungal TAR, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med2001;164:1618-23.CrossRefMedlineWeb of Science
↵Murphy TF, Brauer AL, Grant BJB, Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med2005;172:195-9.CrossRefMedlineWeb of Science
↵Wilkinson TMA, Hurst JR, Perera WR, Wilks M, Donaldson GC, Wedzicha JA. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest J2006;129:317-24.CrossRefWeb of Science
↵Molyneaux PL, Mallia P, Cox MJ, Footitt J, Willis-Owen SAG, Homola D, et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med2013;188:1224-31.CrossRefMedlineWeb of Science
↵Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med2006;173:1114-21.CrossRefMedlineWeb of Science
↵Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J2007;29:1224-38.Abstract/FREE Full Text
↵Aaron SD, Donaldson GC, Whitmore GA, Hurst JR, Ramsay T, Wedzicha JA. Time course and pattern of COPD exacerbation onset. Thorax2012;67:238-43.Abstract/FREE Full Text
↵Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med2000;161:1608-13.CrossRefMedlineWeb of Science
↵Elixhauser A, Steiner C. Readmissions to US hospitals by diagnosis, 2010. Agency For Healthcare Research and Policy, 2013.
↵Aaron SD, Vandemheen K, Hebert P, Dales R, Stiell IG, Ahuja J, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med2003;348:2618-25.CrossRefMedlineWeb of Science
↵Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med1999;340:1941-7.CrossRefMedlineWeb of Science
↵Leuppi JD, Schuetz P, Bingisser R. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA2013;309:2223-31.CrossRefMedlineWeb of Science
↵Prieto-Centurion V, Markos MA, Ramey NI, Gussin HA, Nyenhuis SM, Joo MJ, et al. Interventions to reduce rehospitalizations after chronic obstructive pulmonary disease exacerbations. A systematic review. Ann Am Thorac Soc2014;11:417-24.CrossRefMedline
↵Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez PR, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax2005;60:925-31.Abstract/FREE Full Text
↵Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbations of chronic obstructive pulmonary disease. JAMA1995;274:1852-7.CrossRefMedlineWeb of Science
↵Piquet J, Chavaillon JM, David P, Martin F, Blanchon F, Roche N. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J2013;42:946-55.Abstract/FREE Full Text
↵Jones P. Health status and the spiral of decline. COPD2009;6:59-63.CrossRefWeb of Science
↵Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med2010;363:1128-38.CrossRefMedlineWeb of Science
↵Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet2009;374:1171-8.CrossRefMedlineWeb of Science
↵Jenkins C, Jones P, Calverley P, Celli B, Anderson J, Ferguson G, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res2009;10:59.CrossRefMedline
↵Thomsen M, Ingebrigtsen T, Marott J. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA2013;309:2353-61.CrossRefMedlineWeb of Science
↵O’Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk DD, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2007 update. Can Respir J2007;14:5B-32B.MedlineWeb of Science
↵Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. A randomized, placebo-controlled trial. Am J Respir Crit Care Med2012;186:48-55.CrossRefMedlineWeb of Science
↵Aaron SD, Vandemheen KL, Maltais F, Field SK, Sin DD, Bourbeau J, et al. TNFalpha antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax2013;68:142-8.Abstract/FREE Full Text
↵Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect2011;17:E1-59.CrossRefMedline
↵Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet2001;358:2020-5.CrossRefMedlineWeb of Science